Dr. Alexander Beck

Strategically manage and operate the Large Molecule & ATMP Business Unit across 3 operational sites, leading a team of > 300 employees and driving annual revenue exceeding CHF 75m. + Achieved 20% increase in revenue and profitability compared to 2022. + Led successful turnaround efforts at the French site, improving quality, turnover, profitability, initiated and oversaw qualification & rollout of a LIMS system & expansion program + Developed a comprehensive 5-year strategic growth plan for the BU.

Directed strategic and operational initiatives for the Large Molecule Services Unit, specializing in CMC-related analytical services for Biologics and Cell & Gene Therapies, managing a team of over 300 employees. Transformed operations into centers of excellence by leveraging innovative technologies and services. Achieved a 20% increase in revenue and profitability year-over-year. Stabilized operations to support clinical phase testing of CAR-T cell, mRNA, and gene therapeutic potency assays.

Provided strategic and operational leadership to the Biopharma Service Unit, managing over 100 employees and generating annual revenue exceeding CHF 35 million. + Successfully restructured biopharma services and analytical portfolio, achieving significant sales and profit growth. + Led the upgrade and transformation of Chromeleon CDS into a technology platform. + Standardized project organization processes across functions, resulting in streamlined operations.

Managed a team specializing in Small and Large Molecule Analytics, overseeing GMP quality control activities for biopharmaceuticals. + Initiated successful turnaround by strategically restructuring the service portfolio. + Implemented innovative mass spectrometry technologies and achieved significant sales growth.

Managed the therapeutic drug monitoring team (10 employees, > 130.000 test p.a.) within the Special Clinical Chemistry department, specializing in quantification of drugs and metabolites in human samples using advanced analytical techniques (LC-MS, ELISA). + Increased revenue by 15% to EUR 2.5 million through the implementation of new assays and advanced technologies. + Expanded study business by 200% through the introduction of GLP services as part of SYNLAB Analytics & Services.

Managed analytical services for protein characterization (5 employees), overseeing project mgmt, business development & strategic initiatives. +Secured EUR 5 million expansion financing as an authorized officer and member of the executive board, supporting company growth +Achieved 200% revenue growth & doubled customer portfolio, expanding services and technology offerings +Spearheaded the successful ISO certification process & prepared for GMP certification, ensuring quality & compliance standards